Please Note: There is no Medicare information on our corporate website. Please select a specific contract in the 'Search Within' box for Medicare related information.
© 2019 Palmetto GBA, LLC
We frequently update our articles to reflect the latest changes and updates to Medicare, and strongly recommend you visit this article at link below to confirm you have the latest version.
Printed Date: 9/22/2015
Radium Ra-223 is FDA approved for the treatment of individuals with castration-resistant prostate cancer. For dates of service beginning January 1, 2015, hospital outpatient departments should bill Medicare for Radium Ra-223, using HCPCS code A9606. The revenue code 0636 should also appear on the claim. In addition to needing the dosage noted on the claim, the provider also needs to indicate that bone metastases are present and that visceral metastases are absent in the Remarks field on the UB-04 or its electronic equivalent.
We value your opinion and want to provide the highest-quality and most relevant Medicare knowledge possible. Please let us know if this article was helpful.
It didn't answer my question
This article was helpful
We’re glad we could help you today and appreciate your feedback. When you rate our articles as most helpful, we know that we are on the right track for providing you with important news and information.
We're sorry this article didn't help you today. We'll use your feedback to review this article to try to revise or expand it. Contact us with more feedback or a question on this topic.
Last Updated: 10/16/2019